This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Basu, A. Articles by Lazo, J. S. Search for Related Content PubMed PubMed Citation Articles by Basu, A. Articles by Lazo, J. S.

Sensitization of Human Cervical Carcinoma Cells to cis-Diamminedichloroplatinum(II) by Bryostatin 1¹

Department of Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261

Bryostatins are an important class of protein kinase C (PKC) activators. We have investigated the effect of bryostatin 1 on the antiproliferative activity of cis-diamminedichloroplatinum(II) (CP). A 24-h pretreatment of HeLa cells with 1 nM bryostatin 1 increased cellular sensitivity to CP by 4-fold. The effect of bryostatin 1 on the IC₅₀ of CP (concentration of drug required to inhibit cell proliferation by 50%) was concentration-dependent and biphasic; the maximum effect of bryostatin 1 was seen with 1 nM, but higher concentrations of bryostatin 1 (10 nM) produced less CP sensitization. Although bryostatin 1 and phorbol esters caused an equivalent stimulation of HeLa cell PKC in cell-free systems, bryostatin 1 was less effective than phorbol esters in sensitizing cells to CP. Additionally, higher concentrations of bryostatin 1 (10 nM) antagonized CP sensitization by phorbol esters. Bryostatin 1 was even more potent than 12-O-tetradecanoylphorbol-13-acetate in inducing PKC down-regulation, and the maximum down-regulation was achieved with 10 nM bryostatin 1. Bryostatin 1 also increased cellular sensitivity to a CP analogue, cis-dichloro(ethylenediamine)platinum(II). A 24-h pretreatment with 1 nM bryostatin 1 increased cellular cis-[³H]DEP by 60%. The concentration- and time-dependent enhancement in CP sensitivity by bryostatin 1 was related to the increase in cis-[³H]DEP level. Thus, cellular accumulation of CP may be regulated by a PKC-dependent phosphorylation event.

¹ Supported by Grants R29 CA 54294 (A. B.) from the National Cancer Institute and CH-486 (J. S. L.) from the American Cancer Society.

² To whom requests for reprints should be addressed, at Department of Pharmacology, University of Pittsburgh School of Medicine, E1358 Biomedical Science Tower, Pittsburgh, PA 15261.

Received 12/20/91. Accepted 3/24/92.

This article has been cited by other articles:

				S. Mohanty, J. Huang, and A. Basu Enhancement of Cisplatin Sensitivity of Cisplatin-Resistant Human Cervical Carcinoma Cells by Bryostatin 1 Clin. Cancer Res., September 15, 2005; 11(18): 6730 - 6737. [Abstract] [Full Text] [PDF]

				C. L. Johnson, D. Lu, J. Huang, and A. Basu Regulation of p53 Stabilization by DNA Damage and Protein Kinase C Mol. Cancer Ther., August 1, 2002; 1(10): 861 - 867. [Abstract] [Full Text] [PDF]

				J. A. Koutcher, M. Motwani, K. L. Zakian, X.-K. Li, C. Matei, J. P. Dyke, D. Ballon, H. H. Yoo, and G. K. Schwartz The in Vivo Effect of Bryostatin-1 on Paclitaxel-induced Tumor Growth, Mitotic Entry, and Blood Flow Clin. Cancer Res., April 1, 2000; 6(4): 1498 - 1507. [Abstract] [Full Text]

				S. A. Matthews, G. R. Pettit, and E. Rozengurt Bryostatin 1 Induces Biphasic Activation of Protein Kinase D in Intact Cells J. Biol. Chem., August 8, 1997; 272(32): 20245 - 20250. [Abstract] [Full Text] [PDF]